Clinical Trial Update: Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of cabozantinib before cytoreductive nephrectomy in advanced or metastatic renal cell carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Fundacion Oncosur | Conditions: Renal Cell Carcinoma Metastatic, Renal Cell Carcinoma Stage IV | Phase 2 | Status: TERMINATED